Identification and Development of Therapeutics for COVID-19
Authors:
Halie M. Rando,
Nils Wellhausen,
Soumita Ghosh,
Alexandra J. Lee,
Anna Ada Dattoli,
Fengling Hu,
James Brian Byrd,
Diane N. Rafizadeh,
Ronan Lordan,
Yanjun Qi,
Yuchen Sun,
Christian Brueffer,
Jeffrey M. Field,
Marouen Ben Guebila,
Nafisa M. Jadavji,
Ashwin N. Skelly,
Bharath Ramsundar,
**hui Wang,
Rishi Raj Goel,
YoSon Park,
the COVID-19 Review Consortium,
Simina M. Boca,
Anthony Gitter,
Casey S. Greene
Abstract:
After emerging in China in late 2019, the novel Severe acute respiratory syndrome-like coronavirus 2 (SARS-CoV-2) spread worldwide and as of early 2021, continues to significantly impact most countries. Only a small number of coronaviruses are known to infect humans, and only two are associated with the severe outcomes associated with SARS-CoV-2: Severe acute respiratory syndrome-related coronavir…
▽ More
After emerging in China in late 2019, the novel Severe acute respiratory syndrome-like coronavirus 2 (SARS-CoV-2) spread worldwide and as of early 2021, continues to significantly impact most countries. Only a small number of coronaviruses are known to infect humans, and only two are associated with the severe outcomes associated with SARS-CoV-2: Severe acute respiratory syndrome-related coronavirus, a closely related species of SARS-CoV-2 that emerged in 2002, and Middle East respiratory syndrome-related coronavirus, which emerged in 2012. Both of these previous epidemics were controlled fairly rapidly through public health measures, and no vaccines or robust therapeutic interventions were identified. However, previous insights into the immune response to coronaviruses gained during the outbreaks of severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) have proved beneficial to identifying approaches to the treatment and prophylaxis of novel coronavirus disease 2019 (COVID-19). A number of potential therapeutics against SARS-CoV-2 and the resultant COVID-19 illness were rapidly identified, leading to a large number of clinical trials investigating a variety of possible therapeutic approaches being initiated early on in the pandemic. As a result, a small number of therapeutics have already been authorized by regulatory agencies such as the Food and Drug Administration (FDA) in the United States, and many other therapeutics remain under investigation. Here, we describe a range of approaches for the treatment of COVID-19, along with their proposed mechanisms of action and the current status of clinical investigation into each candidate. The status of these investigations will continue to evolve, and this review will be updated as progress is made.
△ Less
Submitted 10 September, 2021; v1 submitted 3 March, 2021;
originally announced March 2021.
Pathogenesis, Symptomatology, and Transmission of SARS-CoV-2 through Analysis of Viral Genomics and Structure
Authors:
Halie M. Rando,
Adam L. MacLean,
Alexandra J. Lee,
Ronan Lordan,
Sandipan Ray,
Vikas Bansal,
Ashwin N. Skelly,
Elizabeth Sell,
John J. Dziak,
Lamonica Shinholster,
Lucy D'Agostino McGowan,
Marouen Ben Guebila,
Nils Wellhausen,
Sergey Knyazev,
Simina M. Boca,
Stephen Capone,
Yanjun Qi,
YoSon Park,
Yuchen Sun,
David Mai,
Joel D. Boerckel,
Christian Brueffer,
James Brian Byrd,
Jeremy P. Kamil,
**hui Wang
, et al. (9 additional authors not shown)
Abstract:
The novel coronavirus SARS-CoV-2, which emerged in late 2019, has since spread around the world and infected hundreds of millions of people with coronavirus disease 2019 (COVID-19). While this viral species was unknown prior to January 2020, its similarity to other coronaviruses that infect humans has allowed for rapid insight into the mechanisms that it uses to infect human hosts, as well as the…
▽ More
The novel coronavirus SARS-CoV-2, which emerged in late 2019, has since spread around the world and infected hundreds of millions of people with coronavirus disease 2019 (COVID-19). While this viral species was unknown prior to January 2020, its similarity to other coronaviruses that infect humans has allowed for rapid insight into the mechanisms that it uses to infect human hosts, as well as the ways in which the human immune system can respond. Here, we contextualize SARS-CoV-2 among other coronaviruses and identify what is known and what can be inferred about its behavior once inside a human host. Because the genomic content of coronaviruses, which specifies the virus's structure, is highly conserved, early genomic analysis provided a significant head start in predicting viral pathogenesis and in understanding potential differences among variants. The pathogenesis of the virus offers insights into symptomatology, transmission, and individual susceptibility. Additionally, prior research into interactions between the human immune system and coronaviruses has identified how these viruses can evade the immune system's protective mechanisms. We also explore systems-level research into the regulatory and proteomic effects of SARS-CoV-2 infection and the immune response. Understanding the structure and behavior of the virus serves to contextualize the many facets of the COVID-19 pandemic and can influence efforts to control the virus and treat the disease.
△ Less
Submitted 3 December, 2021; v1 submitted 1 February, 2021;
originally announced February 2021.